Drug Profile
Tabelecleucel - Atara Biotherapeutics
Alternative Names: Allogeneic Epstein Barrr virus specific cytotoxic T-lymphocytes - Atara/MSKCC; ATA-129; EBV targeted T-cell therapy - Atara/MSKCC; EBV-CTL - Atara/MSKCC; EBV-specific T-cells - Atara/MSKCC; Ebvallo; EbvalloTM; Epstein-Barr virus specific cytotoxic T-lymphocytes - Atara/MSKCC; Epstein-Barr virus-specific T-cell therapy - Atara Biotherapeutics/Memorial Sloan-Kettering Cancer Center; Tab-cel®Latest Information Update: 25 Dec 2023
Price :
$50
*
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Developer Atara Biotherapeutics; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA)
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Lymphoproliferative disorders
- Phase I/II Nasopharyngeal cancer
Most Recent Events
- 20 Dec 2023 Atara Biotherapeutics completes Commercialisation agreement with Pierre Fabre for USA
- 29 Nov 2023 Pooled adverse events and efficacy data from three phase II trials and an expanded-access protocol in indication) released by PureTech Health
- 19 Sep 2023 Atara Biotherapeutics announces intention to submit BLA to the US FDA for Lymphoproliferative disorder in Q2 2024